Repairing mutated proteins-development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator

Expert Opinion on Drug Discovery

Volumn 8, Issue 6, 2013, Pages 691-708

  Merk, Daniel ^a   Schubert Zsilavecz, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

CFTR; CFTR corrector; CFTR modulator; CFTR potentiator; F508del; G551D; Ivacaftor; Personalized medicine; VX 770; VX 809

Indexed keywords

CASTANOSPERMINE; COPO 22; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FELODIPINE; GENISTEIN; GLAFENINE; IVACAFTOR; KM 11060; LUMACAFTOR; MIGLUSTAT; NIMODIPINE; OUABAIN; PG 01; RP 193; SF 01; SF 03; SILDENAFIL; UNCLASSIFIED DRUG; VRT 325; VX 532; VX 661;

CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REVIEW; TARGETED GENE REPAIR;

CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA REPAIR; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION;

EID: 84877932776     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.788495     Document Type: Review

References (72)

1. Lubamba B, Dhooghe B, Noel S, Leal T. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem 2012;45(15):1132-44
2. Barrett PM, Alagely A, Topol EJ. Cystic fibrosis in an era of genomically guided therapy. Hum Mol Genet 2012;21(R1):R66-71
3. Wang W, Wu J, Bernard K, et al. ATP-independent CFTR channel gating and allosteric modulation by phosphorylation. Proc Natl Acad Sci USA 2010;107(8):3888-93
4. Lewis HA, Buchanan SG, Burley SK, et al. Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J 2004;23(2):282-93
5. Patrick AE. Development of CFTR structure. Front Pharmacol 2012;3:162
6. Atwell S, Brouillette CG, Conners K, et al. Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant. Protein Eng Des Sel 2010;23(5):375-84
7. Barriere H, Bagdany M, Bossard F, et al. Revisiting the role of cystic fibrosis transmembrane conductance regulator and counterion permeability in the pH regulation of endocytic organelles. Mol Biol Cell 2009;20(13):3125-41
8. Hudson RP, Chong PA, Protasevich II, et al. Conformational changes relevant to channel activity and folding within the first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 2012;287(34):28480-94
9. Lewis H, Wang C, Zhao X, et al. Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry. J Mol Biol 2010;396(2):406-30
10. Baker JMR, Hudson RP, Kanelis V, et al. CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices. Nat Struct Mol Biol 2007;14(8):738-45
11. Lewis HA, Zhao X, Wang C, et al. Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. J Biol Chem 2005;280(2):1346-53
12. Thibodeau PH, Brautigam CA, Machius M, Thomas PJ. Side chain and backbone contributions of Phe508 to CFTR folding. Nat Struct Mol Biol 2005;12(1):10-16
13. Carlile GW, Robert R, Zhang D, et al. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. ChemBioChem 2007;8(9):1012-20
14. Pedemonte N, Galietta LJV. Pharmacological correctors of mutant CFTR mistrafficking. Front Pharmacol 2012;3:175
15. Kalid O, Mense M, Fischman S, et al. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des 2010;24(12):971-91
16. Melin P, Norez C, Callebaut I, Becq F. The glycine residues G551 and G1349 within the ATP-binding cassette signature motifs play critical roles in the activation and inhibition of cystic fibrosis transmembrane conductance regulator channels by phloxine B. J Membr Biol 2005;208(3):203-12
17. Available from: http://www.cff.org/ research/DrugDevelopmentPipeline/
18. Rowe SM, Borowitz DS, Burns JL, et al. Progress in cystic fibrosis and the CF therapeutics development network. Thorax 2012;67(10):882-90
19. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective deltaf508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005;115(9):2564-71
20. Pedemonte N, Tomati V, Sondo E, et al. Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations. J Biol Chem 2011;286(17):15215-26
21. Phuan P, Yang B, Knapp JM, et al. Cyanoquinolines with independent corrector and potentiator activities restore phe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis. Mol Pharmacol 2011;80(4):683-93
22. Knapp JM, Wood AB, Phuan P, et al. Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in dF508 cystic fibrosis transmembrane conductance regulator protein. J Med Chem 2012;55(3):1242-51
23. Dormer RL. Sildenafil (viagra) corrects F508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005;60(1):55-9
24. Poschet JF, Timmins GS, Taylor-Cousar JL, et al. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007;293(3):L712
25. Leier G, Bangel-Ruland N, Sobczak K, et al. Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease. Cell Physiol Biochem 2012;29(5-6):775-90
26. Robert R, Carlile GW, Pavel C, et al. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 2007;73(2):478-89
27. Zhang D, Ciciriello F, Anjos SM, et al. Ouabain mimics low temperature rescue of F508del-CFTR in cystic fibrosis epithelial cells. Front Pharmacol 2012;3:176
28. Sampson HM, Robert R, Liao J, et al. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol 2011;18(2):231-42
29. Robert R, Carlile GW, Liao J, et al. Correction of the Phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol Pharmacol 2010;77(6):922-30
30. Norez C, Noel S, Wilke M, et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 2006;580(8):2081-6
31. Norez C, Antigny F, Noel S, et al. A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype. Am J Respir Cell Mol Biol 2009;41(2):217-25
32. Leonard A, Lebecque P, Dingemanse J, Leal T. A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J Cyst Fibros 2012;11(3):231-6
33. van Goor F. Rescue of F508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006;290(6):L1117
34. Chiaw PK, Wellhauser L, Huan LJ, et al. A chemical corrector modifies the channel function of F508del-CFTR. Mol Pharmacol 2010;78(3):411-18
35. Wang Y, Loo TW, Bartlett MC, Clarke DM. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. J Biol Chem 2007;282(46):33247-51
36. Wang Y, Loo TW, Bartlett MC, Clarke DM. Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. Biochem J 2007;406(2):257
37. Yu W, Chiaw PK, Bear CE. Probing conformational rescue induced by a chemical corrector of F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutant. J Biol Chem 2011;286(28):24714-25
38. Sampson HM, Lam H, Chen P, et al. Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines. Orphanet J Rare Dis 2013;8:11
39. van Goor F, Hadida S, Grootenhuis PDJ, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Nat Acad Sci 2011;108(46):18843-8
40. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2011;67(1):12-18
41. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;363(21):1991-2003
42. Rowe SM, Accurso F, Clancy JP. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 2007;4(4):387-98
43. Anjos SM, Robert R, Waller D, et al. Decreasing poly(ADP-Ribose) polymerase activity restores dF508 CFTR trafficking. Front Pharmacol 2012;3:165
44. Carlile GW, Keyzers RA, Teske KA, et al. Correction of F508del-CFTR trafficking by the sponge alkaloid latonduine is modulated by interaction with PARP. Chem Biol 2012;19(10):1288-99
45. Mendoza JL, Schmidt A, Li Q, et al. Requirements for efficient correction of dF508 CFTR revealed by analyses of evolved sequences. Cell 2012;148(1-2):164-74
46. Rabeh WM, Bossard F, Xu H, et al. Correction of both NBD1 energetics and domain interface is required to restore DF508 CFTR folding and function. Cell 2012;148(1-2):150-63
47. Verkman AS, Galietta LJV. Chloride channels as drug targets. Nat Rev Drug Discov 2008;8(2):153-71
48. Schultz BD, Singh AK, Devor DC, Bridges RJ. Pharmacology of CFTR chloride channel activity. Physiol Rev 1999;79(1 Suppl):S109-44
49. Li M, Cowley EA, Linsdell P. Pseudohalide anions reveal a novel extracellular site for potentiators to increase CFTR function. Br J Pharmacol 2012;167(5):1062-75
50. Amaral MD, Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 2007;28(7):334-41
51. Duszyk M, MacVinish L, Cuthbert AW. Phenanthrolines-a new class of CFTR chloride channel openers. Br J Pharmacol 2001;134(4):853-64
52. Becq F, Mettey Y, Gray MA, et al. Development of substituted Benzo[c] quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. J Biol Chem 1999;274(39):27415-25
53. Murthy M, Pedemonte N, MacVinish L, et al. 4-Chlorobenzo[F]isoquinoline (CBIQ): a novel activator of CFTR and dF508 CFTR. Eur J Pharmacol 2005;516(2):118-24
54. Springsteel MF, Galietta LJ, Ma T, et al. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorg Med Chem 2003;11(18):4113-20
55. Jones JR, Schwiebert EM, DuVall MD, et al. Activation of chloride secretion in cystic fibrosis cells and tissues by the substituted imidazole SRI 2931 †. Biochemistry 2003;42(45):13241-9
56. Yang H. Nanomolar affinity small molecule correctors of defective F508-CFTR chloride channel gating. J Biol Chem 2003;278(37):35079-85
57. Pedemonte N, Diena T, Caci E, et al. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations. Mol Pharmacol 2005;68(6):1736-46
58. Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005;67(5):1797-807
59. Suen YF, Robins L, Yang B, et al. Sulfamoyl-4-oxoquinoline-3- carboxamides: novel potentiators of defective DF508-cystic fibrosis transmembrane conductance regulator chloride channel gating. Bioorg Med Chem Lett 2006;16(3):537-40
60. Wang Y. Specific rescue of CFTR processing mutants using pharmacological chaperones. Mol Pharmacol 2006;70(1):297-302
61. Wellhauser L, Chiaw PK, Pasyk S, et al. A Small-molecule modulator interacts directly with Phe508-CFTR to modify its atpase activity and conformational stability. Mol Pharmacol 2009;75(6):1430-8
62. Pasyk S, Li C, Ramjeesingh M, Bear CE. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease. Biochem J 2009;418(1):185-90
63. Mettey Y, Gompel M, Thomas V, et al. Aloisines, a new family of CDK/GSK- 3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem 2003;46(2):222-36
64. Noel S. Discovery of Pyrrolo[2,3-b] pyrazines derivatives as submicromolar affinity activators of wild type, G551D, and F508del cystic fibrosis transmembrane conductance regulator chloride channels. J Pharmacol Exper Ther 2006;319(1):349-59
65. Dannhoffer L, Billet A, Jollivet M, et al. Stimulation of wild-type, F508del- and G551D-CFTR chloride channels by non-toxic modified pyrrolo[2,3-b] pyrazine derivatives. Front Pharmacol 2011;2:48
66. Bertrand J, Boucherle B, Billet A, et al. Identification of a novel water-soluble activator of wild-type and F508del CFTR: GPact-11a. Eur Respir J 2010;36(2):311-22
67. van Goor F, Hadida S, Grootenhuis PDJ, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009;106(44):18825-30
68. Eckford PDW, Li C, Ramjeesingh M, Bear CE. Cystic fibrosis transmembrane conductance regulator (CFTR) Potentiator VX-770 (Ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent Manner. J Biol Chem 2012;287(44):36639-49
69. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365(18):1663-72
70. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012;142(3):718-24
71. Yu H, Burton B, Huang C, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012;11(3):237-45
72. Available from: www.kalydeco.eu